PSMA

Product List

Creative Biolabs provides one-stop CAR-T products and services for our clients. Whether you need help with CAR design and construction, T cell engineering, or anything else related to CAR-T cell development, we have the expertise and experience to get the job done.

Background

Prostate-specific membrane antigen (PSMA) is also known as glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I) or NAAG peptidase. It is a zinc metalloenzyme that is located in membranes, which mainly expressed in the tissues of the prostate epithelium, the proximal tubules of the kidney, the jejunal brush border of the small intestine, and the ganglia of the nervous system. PSMA is associated with prostate cancer as well as neovasculature of most of solid tumors.

Associated Diseases

Prostate cancer

Renal cell carcinoma

Breast cancer

Lung cancer

Colorectal cancer

Anti-PSMA CAR-T Services

Anti-PSMA CAR-T In Vitro Assays

Anti-PSMA CAR-T Expression Test

At Creative Biolabs, our PE-labeled PSMA, FITC-labeled PSMA, protein L and anti-Fab antibodies are effective tools for detecting anti-PSMA CAR expression on the surface of CAR-T cells. These reagents bind specifically to the scfv region of the CAR molecule, allowing for sensitive and accurate detection of CAR expression.

Fig.1 Flow cytometry analysis to evaluate CAR expression. The results show that CAR-T cells express the anti-PSMA CAR at high levels.¹

Anti-PSMA CAR-T Cytokine Release Test

Our cytokine release test services utilize state-of-the-art techniques such as bead-based multiplex assay to measure the levels of key cytokines, including IL-2, IL-4, IL5, and IL-13. By accurately measuring these cytokines, we have the ability to assess the efficiency of the CAR-T treatment in targeting specific cancers and its overall immunological impact.

Fig.2 Multiplex cytokine profiling in PSMA CAR-T cells co-cultured with PC3-PSMA cells. The cytokines IL-2, IL-4, IL-5 and IL-13 are secreted at higher amounts.²

Anti-PSMA CAR-T In Vitro Cytotoxicity Assay

Anti-PSMA CAR-T therapy shows promising efficacy in patients with prostate cancer. At Creative Biolabs, we offer services to evaluate the cytotoxic activity of anti-PSMA CAR-T cells.

Fig.3 Cytolytic activity of anti-PSMA CAR-T against C4-2 cells (PSMA+) cell lines. PSMA CAR-T cells exhibited antigen-specific cytotoxicity and eliminated PSMA-positive prostate cancer cells.¹

Anti-PSMA CAR-T In Vivo Assays

Anti-PSMA CAR-T Cell Therapy Animal Models

We provide the right animal models to study the activity and effects of the anti-PSMA CAR-T products in vivo. We use established assays and models to illuminate CAR-T biology, providing us with a deeper understanding of how the therapy works and its potential side effects.

Fig.4 Schematic of the anti-PSMA CAR-T cell therapy mouse model.²

Efficacy Test of Anti-PSMA CAR-T

Our team of experts has extensive experience in CAR-T in vivo research projects, allowing us to provide comprehensive PSMA CAR-T cell efficacy evaluation services with the best animal models.

Fig.5 In vivo potency of PSMA CAR-T cells. In vivo bioluminescence images showed treatment with PSMA CAR-T cells eliminated the tumors.²

Toxicity Evaluation Anti-PSMA CAR-T

We provide various toxicological study services including on-target and off-target toxicity, tumorigenicity studies, and so on. These assessments can characterize risk and inform clinical trial designs.

References

1. Alzubi, Jamal, et al. "PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model." Molecular Therapy-Oncolytics 18 (2020): 226-235.
2. Kloss, Christopher C., et al. "Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication." Molecular therapy 26.7 (2018): 1855-1866.